Terms ending in 2027
Every in-force patent on Array Biopharma Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,039,639 | Kinase Inhibitors and Methods of Use Thereof In force · High confidence | Array Biopharma, Inc. | In force | High confidence | |
| US 9,693,989 | N4-PHENYL-QUINAZOLINE-4-Amine Derivatives and Related Compounds as Erbb Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases In force · High confidence | Array Biopharma, Inc. | In force | High confidence | |
| US 9,359,340 | Hydroxylated and Methoxylated Pyrimidyl Cyclopentanes as Akt Protein Kinase Inhibitors In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 8,044,083 | Kinase Inhibitors and Methods of Use Thereof In force · High confidence | Array Biopharma, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Array Biopharma Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.